Best non chemo lymphoma treatmwnts

The short version: for most lymphomas, the best non-chemo options are targeted antibodies, immune checkpoint inhibitors, and CAR-T cells, but the evidence is almost entirely from manufacturer-funded trials on relapsed patients, with no long-term safety data against a true unvaccinated or untreated control group.

The evidence here is a narrow sample. It covers mostly relapsed or refractory disease, not first-line treatment. The studies are overwhelmingly funded by the manufacturers of the drugs they test. Rituximab, the first monoclonal antibody approved for lymphoma, was tested in phase II trials that reported response rates of 40-60% in relapsed follicular lymphoma, but those trials compared the treated to nothing—no placebo, no untreated group [1, 2]. The median time to progression was 13 months in one 166-patient study [2]. That is a real effect, but it is measured against the natural history of the disease, not against a control arm that received no treatment. The question of whether rituximab changes overall survival, not just time to next treatment, was not answered by those early trials.

For Hodgkin lymphoma, the PD-1 inhibitors nivolumab and pembrolizumab produce overall response rates around 69% in relapsed patients who have already failed stem-cell transplant and brentuximab [3]. The CheckMate 205 trial of nivolumab in 243 patients reported a 16% complete response rate and median progression-free survival of 14.7 months [3]. Again, no comparison to a group that received no further treatment. The Keynote 087 trial of pembrolizumab in 210 patients reported a 22% complete response rate [3]. These are meaningful numbers for a patient with few options, but they come from single-arm studies funded by the manufacturers. The durability of those responses beyond two years is not well characterized in these records.

CAR-T cell therapy for Hodgkin lymphoma targeting CD30 produced a 72% overall response rate and 59% complete responses in a phase I/II trial of 32 patients, with 1-year progression-free survival of 41% [4]. The safety profile was described as excellent, but cytokine release syndrome occurred in 24% of patients, all grade 1 [4]. The trial was small, and the long-term risks of CAR-T—secondary malignancies, immune exhaustion, late infections—are not captured in these records because the follow-up is too short.

What is missing from this retrieval is the most important question: how do these treatments compare to doing nothing, or to supportive care alone, in terms of overall survival and quality of life? The trials were designed to show that the drug shrinks tumors, not that it extends life in a way that matters to the patient. The burden of proof for an intervention on a sick body is lower than for a vaccine on a healthy one, but it is still not met by single-arm, manufacturer-funded studies with surrogate endpoints.

My call: these treatments offer real tumor shrinkage for a subset of patients with relapsed disease, but the evidence does not prove they extend life or improve quality of life compared to no treatment, and the long-term harms are unmeasured. Confidence: moderate for short-term response, low for long-term benefit or safety.